MacTel Differentiation: It’s the Company You Keep 

Obtaining a diagnosis of macular telangiectasia requires taking the whole picture into consideration, looking for a group of features rather than one definitive sign. 

By Dante J. Pieramici, MD, FASRS

Biosimilars in Retina Care

This expanding category of drugs can make a global impact on retinal disease.

By Ashish Sharma, MD

Optimizing Your Retina Drug Inventory Process 

A practical look at available tools, how they differ, and where practices are leaving cost savings on the table

By Peter A. Karth, MD, MBA, FASRS, FACS

Case Study: Identifying Patients With GA for Complement Inhibition Treatment

Patient selection is critical to optimize our treatment outcomes.

By Jonathan Jonisch, MD, FASRS

Case Study: Early Treatment of Geographic Atrophy

Identifying and treating GA patients early is the most impactful decision a retina specialist can make in managing geographic atrophy.

By Nikolas London, MD